Bundamedik Tbk PT (BMHS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bundamedik Tbk PT (BMHS) has a cash flow conversion efficiency ratio of 0.083x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp199.64 Billion ≈ $11.70 Million USD) by net assets (Rp2.39 Trillion ≈ $140.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Bundamedik Tbk PT fund operations to measure how many days the company can operate on defensive assets alone.
Bundamedik Tbk PT - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bundamedik Tbk PT's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bundamedik Tbk PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bundamedik Tbk PT ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sao Mai Group Corp
VN:ASM
|
-0.024x |
|
q.beyond AG
F:QBY
|
0.035x |
|
Finder Energy Holdings Ltd
AU:FDR
|
-0.630x |
|
Ryvu Therapeutics SA
WAR:RVU
|
-0.553x |
|
RF Acquisition Corp II Ordinary Shares
NASDAQ:RFAI
|
-0.006x |
|
TMT Steel Public Company Limited
BK:TMT
|
0.160x |
|
Vaziva Sa
PA:ALVAZ
|
N/A |
|
Max India Limited
NSE:MAXIND
|
-0.098x |
Annual Cash Flow Conversion Efficiency for Bundamedik Tbk PT (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bundamedik Tbk PT from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see BMHS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Rp2.39 Trillion ≈ $140.31 Million |
Rp250.62 Billion ≈ $14.69 Million |
0.105x | +561.56% |
| 2024-12-31 | Rp2.15 Trillion ≈ $125.85 Million |
Rp33.98 Billion ≈ $1.99 Million |
0.016x | -44.64% |
| 2023-12-31 | Rp1.80 Trillion ≈ $105.47 Million |
Rp51.44 Billion ≈ $3.01 Million |
0.029x | -78.24% |
| 2022-12-31 | Rp1.81 Trillion ≈ $105.96 Million |
Rp237.47 Billion ≈ $13.91 Million |
0.131x | -36.61% |
| 2021-12-31 | Rp1.69 Trillion ≈ $98.84 Million |
Rp349.44 Billion ≈ $20.48 Million |
0.207x | +14.24% |
| 2020-12-31 | Rp1.05 Trillion ≈ $61.51 Million |
Rp190.36 Billion ≈ $11.15 Million |
0.181x | +34.54% |
| 2019-12-31 | Rp665.59 Billion ≈ $39.00 Million |
Rp89.72 Billion ≈ $5.26 Million |
0.135x | +63.82% |
| 2018-12-31 | Rp532.23 Billion ≈ $31.19 Million |
Rp43.79 Billion ≈ $2.57 Million |
0.082x | -- |
About Bundamedik Tbk PT
PT Bundamedik Tbk provides health care services in Indonesia. It also engages private hospital and healthcare support service activities; provision of ambulance services; private health education; consultant for reproductive technology services management; management consultant of physiotherapy service; and hotel, and dental clinic services management consulting businesses. It also provides ferti… Read more